QT Dispersion and QTc Interval in Patients with Adult Sickle Cell Disease: Electrocardiographic (EKG) and Echocardiographic Evaluation


Background: QT dispersion (QTd) varies according to heterogeneity of recovery time in the myocardium, and the impact of iron overload on the QTd in adult patients with Sickle Cell Disease (SCD) is not clear. Aim: This cross-sectional study was designed to evaluate corrected QTc interval and QTd on 12 leads ECG in patients with SCD, and assess the LV systolic and diastolic function using Pulsed Doppler Echocardiogram. Method: All patients were evaluated clinically with pulse Doppler echocardiography. Twelve leads ECG were taken to measure QTd and QTc. Blood samples withdrawn to assess the blood level of ferritin and hemoglobin. Pearson correlation coefficient was used to measure the linear relationship between serum ferritin and QTd. Results: The study included patients with SCD (n = 70, age 15.7 ± 8.9 years), compared with age-matched healthy control group (n = 70, age 15.9 ± 8.9 years). In patients with SCD compared with healthy control group the QTc (msec) 416 ± 23.21 ms vs. 401 ± 24.12 (p = 0.75), and the QTd were slightly longer in SCD compared with the control of 43 ± 22.1 vs. 38 ± 20.16 msec, (p = 0.071) with no significant difference. M mode echo showed that SCD patients compared with control had higher LVMI gm/M2 of 105 ± 10.3 vs. 83 ± 7.1, P = 0.001, larger LV end diastolic dimension (cm) of 5.5 ± 0.32 vs. 4.72 ± 0.35, p = 0.03, RV diameter (cm) of 2.8 ± 0.42 vs. 2.4 ± 0.31, (p = 0.041) and RV wall thickness (mm) of 0.31 ± 0.06 vs. 0.28 ± 0.03, (p = 0.024). Pulsed Doppler showed high LV transmitral E wave velocity of 85.23 ± 1.92 vs. 62.43 ± 1.67 m/s (p = 0.001), A wave (msec) 46.26 ± 4.7 vs. 56.24 ± 3.2 m/s, p = 0.032, with E/A ratio of 1.86 ± 0.01 vs. 1.10 ± 0.03, (p = 0.024) and DT of E wave (msec) of 156.43 ± 23.5 vs. 189.87 ± 19.5, (p = 0.031). Left ventricle ejection fraction percentage was similar between both groups, but SCD had significantly higher right ventricle tricuspid annular plane systolic excursion TAPSE (cm) of 1.23 ± 0.21 vs. 1.11 ± 0.23 cm (p = 0.02), and the tricuspid valve velocity showed significant higher velocity (m/s) in the SCD patients of 2.9 ± 0.14 vs. 1.7 ± 0.09, p = 0.004 indicating higher pulmonary artery pressure with calculated right ventricle systolic pressure of 38.64 vs. 16.56 mmHg. Conclusion: SCD patients compared with control have higher but not significant QT dispersion and corrected QT interval with a significantly larger LV mass and LV diastolic filling indices suggestive of restrictive diastolic pattern. These data indicate that LV diastolic abnormalities compromised initially in patients with SCD.

Share and Cite:

Garadah, T. , Hassan, A. , Alwai, M. , Jaradat, A. , Qurishi, F. and Alajmi, A. (2014) QT Dispersion and QTc Interval in Patients with Adult Sickle Cell Disease: Electrocardiographic (EKG) and Echocardiographic Evaluation. International Journal of Clinical Medicine, 5, 550-557. doi: 10.4236/ijcm.2014.510076.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Bunn, H.F. (1997) Pathogenesis and Treatment of Sickle Cell Disease. The New England Journal of Medicine, 337, 762-769.
[2] Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H., et al. (1994) Mortality in Sickle Cell Disease. Life Expectancy and Risk Factors for Early Death. The New England Journal of Medicine, 330, 1639-1644.
[3] Alhamdan, N.A., Almazrou, Y.Y., Alswaidi, F.M. and Choudhry, A.J. (2007) Premarital Screening for Thalassemia and Sickle Cell Disease in Saudi Arabia. Genetics in Medicine, 9, 372-377.
[4] Nasserullah, Z., Alshammari, A., Abbas, M.A., Abu-Khamseen, Y., Qadri, M., Jafer, S.A., et al. (2003) Regional Experience with Newborn Screening for Sickle Cell Disease, Other Hemoglobinopathies and G6PD Deficiency. Annals of Saudi Medicine, 23, 354-357.
[5] El-Hazmi, M.A., Warsy, A.S., Al-Swailem, A.R., Al-Swailem, A.M. and Bahakim, H.M. (1996) Sickle Cell Gene in the Population of Saudi Arabia. Hemoglobin, 20,187-198.
[6] Pearson, H.A. (1999) Reply: Sickle cell disease in the Kingdom of Saudi Arabia: East and West. Annals of Saudi Medicine, 19, 281-282.
[7] Batra, A.S., Acherman, R.J., Wong, W.Y., Wood, J.C., Chan, L.S., Ramicone, E., et al. (2002) Cardiac Abnormalities in Children with Sickle Cell Anemia. American Journal of Hematology, 70, 306-312.
[8] Zilberman, M.V., Du, W., Das, S. and Sarnaik, S.A. (2007) Evaluation of Left Ventricular Diastolic Function in Pediatric Sickle Cell Disease Patients. American Journal of Hematology, 82, 433-438.
[9] Bahl, V.K., Malhotra, O.P., Kumar, D., Agarwal, R., Goswami, K.C., Bajaj, R., et al. (1992) Noninvasive Assessment of Systolic and Diastolic Left Ventricular Function in Patients with Chronic Severe Anemia: A Combined M-Mode, Two-Dimensional, and Doppler Echocardiographic Study. American Heart Journal, 124, 1516-1523.
[10] Lindqvist, P., Henein, M.Y. and Wikstrom, G. (2009) Right Ventricular Myocardial Velocities and Timing Estimate Pulmonary Artery Systolic Pressure. International Journal of Cardiology, 137, 130-136.
[11] Choong, C.Y., Herrmann, H.C., Weyman, A.E. and Fifer, M.A. (1987) Preload Dependence of Doppler-Derived Indexes of Left Ventricular Diastolic Function in Humans. Journal of the American College of Cardiology, 10, 800-808.
[12] Nishimura, R.A., Schwartz, R.S., Tajik, A.J. and Holmes Jr, D.R. (1993) Noninvasive Measurement of Rate of Left Ventricular Relaxation by Doppler Echocardiography. Validation with Simultaneous Cardiac Catheterization. Circulation, 88, 146-155.
[13] Kautzner, J. and Malik, M. (1997) QT Interval Dispersion and Its Clinical Utility. Pacing and Clinical Electrophysiology, 20, 2625-2640.
[14] Malik, M. and Batchvarov, V.N. (2000) Measurement, Interpretation and Clinical Potential of QT Dispersion. Journal of the American College of Cardiology, 36, 1749-1766.
[15] Ashikaga, T., Nishizaki, M., Arita, M., Yamawake, N., Suzuki, M., Hashimoto, Y., et al. (1999) Effect of Dipyridamole on QT Dispersion in Vasospastic Angina Pectoris. American Journal of Cardiology, 84, 807-810.
[16] Galinier, M., Vialette, J.C., Fourcade, J., Cabrol, P., Dongay, B., Massabuau, P., et al. (1998) QT Interval Dispersion as a Predictor of Arrhythmic Events in Congestive Heart Failure. Importance of Aetiology. European Heart Journal, 19, 1054-1062.
[17] Haverkamp, W., Breithardt, G., Camm, A.J., Janse, M.J., Rosen, M.R., Antzelevitch, C., et al. (2000) The Potential for QT Prolongation and Proarrhythmia by Non-Antiarrhythmic Drugs: Clinical and Regulatory Implications. Report on a Policy Conference of the European Society of Cardiology. European Heart Journal, 21, 1216-1231.
[18] Yi, G., Elliott, P., McKenna, W.J., Prasad, K., Sharma, S., Guo, X.H., et al. (1998) QT Dispersion and Risk Factors for Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 82, 1514-1519.
[19] Langen, K.J., Ziegler, D., Weise, F., Piolot, R., Boy, C., Hübinger, A., et al. (1997) Evaluation of QT Interval Length, QT Dispersion and Myocardial M-Iodobenzylguanidine Uptake in Insulin-Dependent Diabetic Patients with and without Autonomic Neuropathy. Clinical Science (London, England: 1979), 93, 325-333.
[20] Wu, V.C., Lin, L.Y. and Wu, K.D. (2005) QT Interval Dispersion in Dialysis Patients. Nephrology, 10, 109-112.
[21] Bazett, H.C. (1920) The Time Relations of the Blood-Pressure Changes after Excision of the Adrenal Glands, with Some Observations on Blood Volume Changes. The Journal of Physiology, 53, 320-339.
[22] Shipley, R.A. and Hallaran, W.R. (1936) The Four-Lead Electrocardiogram in Two Hundred Normal Men and Women. American Heart Journal, 11, 325-345.
[23] Pye, M., Quinn, A.C. and Cobbe, S.M. (1994) QT Interval Dispersion: A Non-Invasive Marker of Susceptibility to Arrhythmia in Patients with Sustained Ventricular Arrhythmias? British Heart Journal, 71, 511-514.
[24] Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., et al. (2005) Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. Journal of the American Society of Echocardiography, 18, 1440-1463.
[25] Devereux, R.B., Alonso, D.R., Lutas, E.M., Gottlieb, G.J., Campo, E., Sachs I., et al. (1986) Echocardiographic Assessment of Left Ventricular Hypertrophy: Comparison to Necropsy Findings. American Journal of Cardiology, 57, 450-458.
[26] Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., et al. (2004) Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. The New England Journal of Medicine, 350, 886-895.
[27] Metivier, F., Marchais, S.J., Guerin, A.P., Pannier, B. and London, G.M. (2000) Pathophysiology of Anaemia: Focus on the Heart and Blood Vessels. Nephrology Dialysis Transplantation, 15, 14-18.
[28] Aessopos, A., Deftereos, S., Farmakis, D., Corovesis, C., Tassiopoulos, S., Tsironi, M., et al. (2004) Cardiovascular Adaptation to Chronic Anemia in the Elderly: An Echocardiographic Study. Clinical & Investigative Medicine, 27, 265-273.
[29] Kocharian, A., Rooyfard, M.D. and Aghanouri, R. (2003) Prolonged Dispersion of QT and QTc in Thalassemia Major Patients. Acta Medica Iranica, 41, 233-237.
[30] Yaprak, I., Aksit, S., Oztürk, C., Bakiler, A.R., Dorak, C. and Turker, M. (1998) Left Ventricular Diastolic Abnormalities in Children with Beta-Thalassemia Major: A Doppler Echocardiographic Study. The Turkish Journal of Pediatrics, 40, 201-209.
[31] Spirito, P., Lupi, G., Melevendi, C. and Vecchio, C. (1990) Restrictive Diastolic Abnormalities Identified by Doppler Echocardiography in Patients with Thalassemia Major. Circulation, 82, 88-94.
http://dx.doi.org/10.1161/01.CIR.82.1.88 http://www.ncbi.nlm.nih.gov/pubmed/2364528
[32] Bosi, G., Crepaz, R., Gamberini, M.R., Fortini, M., Scarcia, S., Bonsante, E., et al. (2003) Left Ventricular Remodelling, and Systolic and Diastolic Function in Young Adults with Beta Thalassaemia Major: A Doppler Echocardiographic Assessment and Correlation with Haematological Data. Heart, 89, 762-766.
[33] Mandinov, L., Kaufmann, P., Brunner, F. and Hess, O.M. (1997) [Anemia and Heart Function]. Praxis (Bern 1994), 86, 1687-1692.
[34] Akgül, F., Yalçin, F., Babayigit, C., Seyfeli, E., Seydaliyeva, T. and Gali, E. (2006) Right Ventricular and Pulmonary Function in Sickle Cell Disease Patients with Pulmonary Hypertension. Pediatric Cardiology, 27, 440-446.
[35] Sachdev, V., Machado, R.F., Shizukuda, Y., Rao, Y.N., Sidenko, S., Ernst, I., et al. (2007) Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease. Journal of the American College of Cardiology, 49, 472-479.
[36] Gladwin, M.T., Schechter, A.N., Ognibene, F.P., Coles, W.A., Reiter, C.D., Schenke, W.H., et al. (2003) Divergent Nitric Oxide Bioavailability in Men and Women with Sickle Cell Disease. Circulation, 107, 271-278.
[37] Lin, G., Macdonald, R.L., Marton, L.S., Kowalczuk, A., Solenski, N.J. and Weir, B.K. (2001) Hemoglobin Increases Endothelin-1 in Endothelial Cells by Decreasing Nitric Oxide. Biochemical and Biophysical Research Communications, 280, 824-830.
[38] Aessopos, A. and Farmakis, D. (2005) Pulmonary Hypertension in Beta-Thalassemia. Annals of the New York Academy of Sciences, 1054, 342-349.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.